Provided by Tiger Trade Technology Pte. Ltd.

Taysha Gene Therapies, Inc.

4.46
+0.02500.56%
Volume:1.95M
Turnover:8.81M
Market Cap:1.45B
PE:-10.80
High:4.57
Open:4.42
Low:4.36
Close:4.43
52wk High:7.30
52wk Low:3.69
Shares:325.83M
Float Shares:233.00M
Volume Ratio:0.63
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4126
EPS(LYR):-0.3409
ROE:-47.05%
ROA:-23.82%
PB:3.75
PE(LYR):-13.07

Loading ...

Taysha Gene Therapies, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Taysha Gene Therapies Q2 Loss Widens

MT Newswires Live
·
Aug 12

Earnings Flash (TSHA) Taysha Gene Therapies Posts Q2 Loss of $0.13, vs. FactSet Est of $0.11 Loss

MT Newswires Live
·
Aug 12

Taysha Gene Therapies Q2 Net Income USD -46.639 Million

Reuters
·
Aug 12

Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate

Benzinga Earnings
·
Aug 12

Taysha Gene Therapies Rugi Bersih Q2 FY26 Melebar Ke USD 46,64 Juta; Belanja R&D Naik 92,11% Menjadi USD 38,64 Juta

Reuters
·
Aug 12

Taysha Gene Therapies Q2 Operating Expenses USD 47.349 Million

THOMSON REUTERS
·
Aug 12

Taysha Gene Therapies Q2 EPS USD -0.13

THOMSON REUTERS
·
Aug 12

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 12

Taysha Gene Therapies Grants New Hire 144,000 RSUs, 92,400 Stock Options Priced at $5.78

Reuters
·
Aug 07

Taysha Gene Therapies Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 07

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 07

Taysha Gene Therapies to Report Q2 Results, Host Corporate Update Call and Webcast

Reuters
·
Aug 05

Taysha Gene Therapies Taps Catalent for TSHA-102 Rett Syndrome Commercial Manufacturing Support

Reuters
·
Aug 03

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of Tsha-102 Gene Therapy for Rett Syndrome

THOMSON REUTERS
·
Aug 03

Taysha Gene Therapies Posts Corporate Deck Highlighting Tsha-102 Gene Therapy Program for Rett Syndrome

Reuters
·
Jul 25

Taysha Gene Therapies is Maintained at Buy by Goldman Sachs

Dow Jones
·
Jul 21

Taysha Gene Therapies falls -11.0%

TIPRANKS
·
Jul 14

Taysha Gene Therapies President, Head of R&D Sukumar Nagendran Disposes of 200,000 Common Shares for $1.25 Million

Reuters
·
Jul 11

Taysha Gene Therapies (TSHA) Could Be 49% Below Fair Value After Russell Index Drop

Simply Wall St.
·
Jul 10